FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225681775> ?p ?o ?g. }

• W4225681775 endingPage "34" @default.
• W4225681775 startingPage "24" @default.
• W4225681775 abstract "Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the DAPA-CKD and DAPA-HF trials.This study is a pooled analysis of individual participant data from two phase 3, randomised, double-blind, placebo-controlled, multicentre, clinical trials. Participants with no history of diabetes and HbA1c less than 6·5% (48 mmol/mol) at baseline were included in this pooled analysis. New-onset type 2 diabetes was a prespecified exploratory endpoint in both DAPA-CKD and DAPA-HF trials and is the focus of this analysis. New-onset type 2 diabetes was identified by serial trial measurements of HbA1c (two consecutive values ≥6·5% [≥48 mmol/mol]) or following a clinical diagnosis of diabetes between trial visits. Time to new-onset type 2 diabetes was analysed in a Cox proportional Hazards model from random assignment to end of treatment.4003 participants (1398 [34·9%] from the DADA-CKD trial and 2605 [65·1%] from the DAPA-HF trial) were included in our analysis: 1995 (49·8%) had received dapagliflozin and 2008 (50·2%) had received placebo. Over a median follow-up of 21·2 months (IQR 16·0 to 25·4), 126 (6·3%) of 2008 patients in the placebo group (event rate 3·9 per 100 patient-years) and 85 (4·3%) of 1995 patients in the dapagliflozin group (event rate 2·6 per 100 patient-years) developed type 2 diabetes (hazard ratio 0·67 [95% CI 0·51 to 0·88]; p=0·0040). There was no heterogeneity between studies (p interaction 0·77) and there was no clear evidence that the effect of dapagliflozin varied in prespecified subgroups including sex, age, glycaemic status, BMI, glomerular filtration rate, systolic blood pressure, and baseline cardiovascular medication use. More than 90% of the participants who developed type 2 diabetes had prediabetes at baseline (HbA1c 5·7% to 6·4% [39 to 46 mmol/mol]). Mean HbA1c remained unchanged (placebo-adjusted change in the dapagliflozin group of -0·01% [95% CI -0·03 to 0·01], -0·1 mmol/mol [95% CI -0·3 to 0·1] at 12 months).Treatment with dapagliflozin reduced the incidence of new-onset type 2 diabetes in participants with chronic kidney disease and HF without a reduction in HbA1c.AstraZeneca." @default.
• W4225681775 created "2022-05-05" @default.
• W4225681775 creator A5005006476 @default.
• W4225681775 creator A5007964446 @default.
• W4225681775 creator A5008309890 @default.
• W4225681775 creator A5012551917 @default.
• W4225681775 creator A5017272571 @default.
• W4225681775 creator A5018432247 @default.
• W4225681775 creator A5018701033 @default.
• W4225681775 creator A5018872642 @default.
• W4225681775 creator A5023537462 @default.
• W4225681775 creator A5024144703 @default.
• W4225681775 creator A5025161064 @default.
• W4225681775 creator A5030057930 @default.
• W4225681775 creator A5030399648 @default.
• W4225681775 creator A5034537174 @default.
• W4225681775 creator A5034939991 @default.
• W4225681775 creator A5048450888 @default.
• W4225681775 creator A5049652855 @default.
• W4225681775 creator A5052533254 @default.
• W4225681775 creator A5054830306 @default.
• W4225681775 creator A5060560730 @default.
• W4225681775 creator A5062276281 @default.
• W4225681775 creator A5064862183 @default.
• W4225681775 creator A5069865054 @default.
• W4225681775 creator A5069942574 @default.
• W4225681775 creator A5084032669 @default.
• W4225681775 creator A5085592050 @default.
• W4225681775 date "2022-01-01" @default.
• W4225681775 modified "2023-10-18" @default.
• W4225681775 title "Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials" @default.
• W4225681775 cites W2038981426 @default.
• W4225681775 cites W2115607452 @default.
• W4225681775 cites W2123744385 @default.
• W4225681775 cites W2139561039 @default.
• W4225681775 cites W2146264128 @default.
• W4225681775 cites W2148328779 @default.
• W4225681775 cites W2153769155 @default.
• W4225681775 cites W2158822657 @default.
• W4225681775 cites W2166498497 @default.
• W4225681775 cites W2166613497 @default.
• W4225681775 cites W2171512681 @default.
• W4225681775 cites W2425644022 @default.
• W4225681775 cites W2590664415 @default.
• W4225681775 cites W2757331031 @default.
• W4225681775 cites W2889358278 @default.
• W4225681775 cites W2901946789 @default.
• W4225681775 cites W2923389432 @default.
• W4225681775 cites W2939222610 @default.
• W4225681775 cites W2940974223 @default.
• W4225681775 cites W2948612418 @default.
• W4225681775 cites W2957825956 @default.
• W4225681775 cites W2974260792 @default.
• W4225681775 cites W3005350465 @default.
• W4225681775 cites W3081745704 @default.
• W4225681775 cites W3081830235 @default.
• W4225681775 cites W3088173406 @default.
• W4225681775 cites W3093156849 @default.
• W4225681775 cites W3115855235 @default.
• W4225681775 cites W3193297191 @default.
• W4225681775 doi "https://doi.org/10.1016/s2213-8587(21)00295-3" @default.
• W4225681775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34856173" @default.
• W4225681775 hasPublicationYear "2022" @default.
• W4225681775 type Work @default.
• W4225681775 citedByCount "28" @default.
• W4225681775 countsByYear W42256817752022 @default.
• W4225681775 countsByYear W42256817752023 @default.
• W4225681775 crossrefType "journal-article" @default.
• W4225681775 hasAuthorship W4225681775A5005006476 @default.
• W4225681775 hasAuthorship W4225681775A5007964446 @default.
• W4225681775 hasAuthorship W4225681775A5008309890 @default.
• W4225681775 hasAuthorship W4225681775A5012551917 @default.
• W4225681775 hasAuthorship W4225681775A5017272571 @default.
• W4225681775 hasAuthorship W4225681775A5018432247 @default.
• W4225681775 hasAuthorship W4225681775A5018701033 @default.
• W4225681775 hasAuthorship W4225681775A5018872642 @default.
• W4225681775 hasAuthorship W4225681775A5023537462 @default.
• W4225681775 hasAuthorship W4225681775A5024144703 @default.
• W4225681775 hasAuthorship W4225681775A5025161064 @default.
• W4225681775 hasAuthorship W4225681775A5030057930 @default.
• W4225681775 hasAuthorship W4225681775A5030399648 @default.
• W4225681775 hasAuthorship W4225681775A5034537174 @default.
• W4225681775 hasAuthorship W4225681775A5034939991 @default.
• W4225681775 hasAuthorship W4225681775A5048450888 @default.
• W4225681775 hasAuthorship W4225681775A5049652855 @default.
• W4225681775 hasAuthorship W4225681775A5052533254 @default.
• W4225681775 hasAuthorship W4225681775A5054830306 @default.
• W4225681775 hasAuthorship W4225681775A5060560730 @default.
• W4225681775 hasAuthorship W4225681775A5062276281 @default.
• W4225681775 hasAuthorship W4225681775A5064862183 @default.
• W4225681775 hasAuthorship W4225681775A5069865054 @default.
• W4225681775 hasAuthorship W4225681775A5069942574 @default.
• W4225681775 hasAuthorship W4225681775A5084032669 @default.
• W4225681775 hasAuthorship W4225681775A5085592050 @default.
• W4225681775 hasBestOaLocation W42256817752 @default.
• W4225681775 hasConcept C126322002 @default.
• W4225681775 hasConcept C134018914 @default.
• W4225681775 hasConcept C142724271 @default.

• next